NCT04719273 - Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Refractory Endometrial AdenocarcinomaRefractory Endometrial CarcinomaRefractory Endometrial Clear Cell AdenocarcinomaRefractory Endometrial Endometrioid AdenocarcinomaRefractory Endometrial Mixed Cell AdenocarcinomaRefractory Endometrial Serous AdenocarcinomaRefractory Endometrial Undifferentiated Carcinoma

Interventions

DRUG

Extended-release Onapristone

Given PO

DRUG

Anastrozole

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DIAGNOSTIC_TEST

Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)

Immunohistochemistry (IHC):Integral : Tissue

DIAGNOSTIC_TEST

Progesterone Receptor Positive ( PGR Positive; PR Positive)

Immunohistochemistry (IHC)

Trial Locations (2)

19001

Jefferson Abington Hospital, Abington

19107

Thomas Jefferson University, Philadelphia